Tinavi Medical Technologies Co., Ltd. Class A

As of June 30, 2026, Tinavi Medical Technologies Co., Ltd. Class A carries a market capitalization of 7.98B, placing it among publicly traded companies globally. Its enterprise value stands at 7.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Tinavi Medical Technologies Co., Ltd. Class A's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Tinavi Medical Technologies Co., Ltd. Class A has 466.44M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 29.86, and the price-to-book ratio stands at 6.68.

These figures are as of June 30, 2026. The EV/Sales ratio of 30.19 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.95B versus a market cap of 7.98B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Tinavi Medical Technologies Co., Ltd. Class A maintains a current ratio of 2.84, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.48, indicating elevated leverage, while an interest coverage ratio of -9.86 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Tinavi Medical Technologies Co., Ltd. Class A posted a negative return on equity (ROE) of -14.65, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.72, reflecting losses generated across the asset base. The company generates approximately 804,694.00 in revenue per employee across its workforce of 327.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.64 indicates how many times Tinavi Medical Technologies Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Tinavi Medical Technologies Co., Ltd. Class A recorded 41.79M in income tax expense. The company reported a pretax loss of -159.67M and -183.14M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Tinavi Medical Technologies Co., Ltd. Class A's stock has declined approximately 14.68% over the past 52 weeks. The 50-day moving average sits at 15.45, while the 200-day moving average is 18.96.

Over the twelve months ended June 30, 2026, Tinavi Medical Technologies Co., Ltd. Class A generated 263.34M in revenue and converted that into -183.14M in net income, yielding earnings per share of -0.44. EBITDA reached -159.69M, while operating income came in at -174.03M.

As of June 30, 2026, Tinavi Medical Technologies Co., Ltd. Class A holds 245.74M in cash and equivalents against 189.32M in total debt, resulting in a net debt position of -65.49M. Total book value stands at 1.19B, with working capital of 269.22M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Tinavi Medical Technologies Co., Ltd. Class A posted a gross margin of 68.14, reflecting its pricing power and cost economics. The operating margin of -66.09 and net profit margin of -69.55 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Tinavi Medical Technologies Co., Ltd. Class A paid dividends of 0.02 per share. The dividend payout ratio of -3.17 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.95, meaning Tinavi Medical Technologies Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Tinavi Medical Technologies Co., Ltd. Class A has an Altman Z-Score of 9.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.